BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 37498350)

  • 1. Current neoadjuvant therapy for operable locally advanced esophageal cancer.
    Yang W; Niu Y; Sun Y
    Med Oncol; 2023 Jul; 40(9):252. PubMed ID: 37498350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
    He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
    Front Immunol; 2022; 13():853922. PubMed ID: 35720312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.
    Yang J; Huang A; Yang K; Jiang K
    BMC Cancer; 2023 Mar; 23(1):249. PubMed ID: 36922805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative therapy for esophageal cancer.
    Yamasaki M; Miyata H; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Gen Thorac Cardiovasc Surg; 2014 Sep; 62(9):531-40. PubMed ID: 25065567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant chemoradiotherapy or chemotherapy for locally advanced esophageal cancer?].
    Babic B; Fuchs HF; Bruns CJ
    Chirurg; 2020 May; 91(5):379-383. PubMed ID: 32140748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer].
    Fu JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):805-10. PubMed ID: 24061981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
    van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
    Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
    Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
    BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer.
    Smithers BM; Thomson I
    Thorac Surg Clin; 2013 Nov; 23(4):509-23. PubMed ID: 24199701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma.
    Leng XF; Daiko H; Han YT; Mao YS
    Ann N Y Acad Sci; 2020 Dec; 1482(1):213-224. PubMed ID: 33067818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.
    Cheng D; Zhao W; Chen R; Li D; Tang S; Fang C; Ji M
    World J Surg Oncol; 2023 Feb; 21(1):33. PubMed ID: 36737768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer.
    Dai H; Liu M; Li X; Li T; Huang W; Liao J; Li Y; Fang S
    World J Surg Oncol; 2022 Aug; 20(1):267. PubMed ID: 36008813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer.
    Qi S; Mao Y; Jiang M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1115-1123. PubMed ID: 31502113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
    Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
    Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
    Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
    Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.